Background: IgG4-related disease (IgG4-RD) is a recently recognized systemic disease of unknown etiology and prevalence [1]. Retrospective single center series have provided evidence that 13-63% of patients with idiopathic retroperitoneal fibrosis (IRPF) could be reclassified as IgG4-RD. Since immunesuppressants or B-cell targeted therapies may halt or reverse progression, early diagnosis and treatment is important to prevent terminal fibrosis. 
Background: Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) axis have been a major advance in cancer immunotherapy. By enhancing T cell activity, unprecedented long-lasting tumour responses are observed in selected cancers but some patients experience immune related adverse events (irAE). Objectives: To evaluate the prevalence and type of rheumatic and musculoskeletal disorders in patients receiving ICI at a single institution (University Hospital of Bordeaux, France). Methods: All cancer patients with musculoskeletal disorders while receiving ICI were referred to our rheumatology department. For each referred patient, an experienced rheumatologist performed a comprehensive clinical evaluation. Blood tests (inflammatory markers, serum creatine kinase, autoantibodies) and imaging (X-rays, ultrasound) were obtained according to clinical findings. HLA-DR phenotyping was also performed for some patients to search for shared epitope. Results: From September 2015 to December 2016, 329 patients received ICI (anti CTLA-4: n=38; anti PD-1: n=251; anti PD-L1: n=29; combination anti CTLA-4/anti PD-1: n=11) and 21 patients were referred to our rheumatology department (6.4%). Mean age was 65 years and cancer types included melanoma (n=10), non small cell lung cancer (n=9), Merkel carcinoma (n=1) and renal carcinoma (n=1). All musculoskeletal disorders occurred in patients receiving anti PD-1 (nivolumab: n=12; pembrolizumab: n=6) or anti PD-L1 (avelumab: n=2; atezolizumab: n=1), with a median exposure time of 90 days (range: 1-650 days). There were two distinct clinical presentations: 1) inflammatory arthritis (IA) mimicking either rheumatoid arthritis (n=5) or polymyalgia rheumatica (n=8) and, 2) non-inflammatory musculoskeletal conditions (n=8). Of note, one patient was anti-CCP positive but negative for RF. Shared epitope HLA-DRB1 *01:01 was present in 4 patients. Eleven patients required corticosteroid therapy with a median dose of 15mg/day (range: 7-30 mg/day). Non-inflammatory disorders were easily managed with NSAIDs, analgesics and/or physiotherapy. ICI treatment was temporarily discontinued in one patient only, in line with the clinical trial protocol. To date, there was a partial or complete tumour response to ICI in 10 patients whereas 3 had stable disease and 7 had progressive disease. Tumour response or stable disease was observed in 11 of 12 patients with IA but only in 2 of 8 patients with non-inflammatory conditions. Conclusions: In our series, patients with immune-related IA mimicking rheumatoid arthritis and polymyalgia rheumatica were responsive to low-to-moderate dose of prednisone and did not require ICI discontinuation. Furthermore, tumour response was frequently observed in such patients. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.6703 A reaction was observed in 22 vaccine injections (14%) administered to 18 patients. 13 vaccine reactions (68% of all pneumococcal vaccine injections) occurred in 12 patients receiving pneumococcal vaccines. 12 PPV injections (80% of all PPV injections) elicited a vaccine reaction while none was elicited by the PCV injections The high frequency of pneumococcal vaccine reactions contrasted with that of the reactions to other vaccine types: only 17% and 7% of the tetanus/diphtheria and influenza vaccinations, respectively, elicited a vaccine reaction. The odds ratios to react to the pneumococcal vaccines compared to influenza and tetanus/diphtheria vaccines were 31.0 (95% confidence interval (CI) 8-119) and 10.8 (95% CI 2-74). Vaccine reactions after pneumococcal vaccinations were more severe and lasted significantly longer compared to the reactions after other vaccinations. Fever was elicited by almost half of all PPV injections. All symptoms after pneumococcal vaccination were observed very rapidly, usually within hours. Unlike the symptoms observed after influenza and tetanus/diphtheria vaccination, which resolved rapidly, the symptoms related to PPV were much more prolonged and in some cases lasted more than 3 weeks. In 2 patients, pneumococcal vaccination also elicited symptoms consistent with systemic inflammation due to CAPS reactivation. All 5 vaccine related serious adverse events were associated with pneumococcal vaccination.
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